{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Phase+I+Arm+B&page=2",
    "query": {
      "intervention": "Phase I Arm B",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Phase+I+Arm+B&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-26T09:13:14.343Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06868485",
      "title": "A Study to Assess the Efficacy of WSD0922-FU in Patients With C797S+ Advanced Non-small Cell Lung Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Non Small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "WSD0922-FU Tablets, Dose level A",
          "type": "DRUG"
        },
        {
          "name": "WSD0922-FU Tablets, Dose level B",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Wayshine Biopharm, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2025-08-18",
      "completion_date": "2027-12-31",
      "has_results": false,
      "last_update_posted_date": "2025-09-08",
      "last_synced_at": "2026-09-26T09:13:14.343Z",
      "location_count": 8,
      "location_summary": "Oxnard, California • Weston, Florida • Detroit, Michigan + 5 more",
      "locations": [
        {
          "city": "Oxnard",
          "state": "California"
        },
        {
          "city": "Weston",
          "state": "Florida"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "Manahawkin",
          "state": "New Jersey"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06868485"
    },
    {
      "nct_id": "NCT02650401",
      "title": "Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Solid Tumors",
        "CNS Tumors"
      ],
      "interventions": [
        {
          "name": "Entrectinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "0 Years",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "0 Years to 18 Years"
      },
      "enrollment_count": 69,
      "start_date": "2016-05-03",
      "completion_date": "2027-06-30",
      "has_results": false,
      "last_update_posted_date": "2026-09-23",
      "last_synced_at": "2026-09-26T09:13:14.343Z",
      "location_count": 15,
      "location_summary": "La Jolla, California • San Francisco, California • Aurora, Colorado + 12 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02650401"
    },
    {
      "nct_id": "NCT07095868",
      "title": "Evaluate the Safety, Tolerability, and Preliminary Efficacy of EVM14 Alone and in Combination in Patients With Selected Solid Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Selected Types of Solid Tumor"
      ],
      "interventions": [
        {
          "name": "EVM14",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pembrolizumab",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "Everest Medicines (Beijing) Co., Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 94,
      "start_date": "2025-11-17",
      "completion_date": "2031-11",
      "has_results": false,
      "last_update_posted_date": "2026-08-04",
      "last_synced_at": "2026-09-26T09:13:14.343Z",
      "location_count": 3,
      "location_summary": "New York, New York • Houston, Texas • Fairfax, Virginia",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Fairfax",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07095868"
    },
    {
      "nct_id": "NCT04855136",
      "title": "Safety and Efficacy of bb2121 (Ide-cel) Combinations in Multiple Myeloma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "BB2121",
          "type": "BIOLOGICAL"
        },
        {
          "name": "CC-220",
          "type": "DRUG"
        },
        {
          "name": "BMS-986405",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Celgene",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 21,
      "start_date": "2021-06-01",
      "completion_date": "2025-04-25",
      "has_results": false,
      "last_update_posted_date": "2026-07-09",
      "last_synced_at": "2026-09-26T09:13:14.343Z",
      "location_count": 15,
      "location_summary": "Birmingham, Alabama • San Francisco, California • Jacksonville, Florida + 9 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04855136"
    },
    {
      "nct_id": "NCT04421820",
      "title": "BOLD-100 in Combination With FOLFOX for the Treatment of Advanced Solid Tumours",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Colorectal Cancer",
        "Pancreatic Cancer",
        "Gastric Cancers",
        "Cholangiocarcinoma"
      ],
      "interventions": [
        {
          "name": "BOLD-100 +/- FOLFOX Chemotherapy (Arm VII)",
          "type": "DRUG"
        },
        {
          "name": "BOLD-100 in combination with FOLFOX Chemotherapy (Arms I-VI)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bold Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 220,
      "start_date": "2020-08-28",
      "completion_date": "2026-09-01",
      "has_results": false,
      "last_update_posted_date": "2026-05-18",
      "last_synced_at": "2026-09-26T09:13:14.343Z",
      "location_count": 2,
      "location_summary": "Santa Monica, California • Tampa, Florida",
      "locations": [
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04421820"
    },
    {
      "nct_id": "NCT06946524",
      "title": "A Study to Assess the Bioavailability of Risankizumab Following Subcutaneous Administration With Prefilled Pen Relative to a Prefilled Syringe in Healthy Adult Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "Risankizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AbbVie",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 59,
      "start_date": "2025-05-08",
      "completion_date": "2025-11-25",
      "has_results": false,
      "last_update_posted_date": "2025-12-26",
      "last_synced_at": "2026-09-26T09:13:14.343Z",
      "location_count": 2,
      "location_summary": "Cypress, California • Grayslake, Illinois",
      "locations": [
        {
          "city": "Cypress",
          "state": "California"
        },
        {
          "city": "Grayslake",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06946524"
    },
    {
      "nct_id": "NCT01757288",
      "title": "Phase I/II NabPaclitaxel, Paclitaxel&Carboplatin w RTX Followed by Consolidation in Patients w Favorable Prognosis Inoperable Stage IIIA/B NSCLC",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "STAGE IIIA/B NSCLC / INOPERABLE LUNG CANCER"
      ],
      "interventions": [
        {
          "name": "NAB-PACLITAXEL",
          "type": "DRUG"
        },
        {
          "name": "PACLITAXEL",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Texas Southwestern Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 98,
      "start_date": "2013-03-25",
      "completion_date": "2019-06-03",
      "has_results": true,
      "last_update_posted_date": "2021-10-28",
      "last_synced_at": "2026-09-26T09:13:14.343Z",
      "location_count": 5,
      "location_summary": "Rochester, New York • Pittsburgh, Pennsylvania • Nashville, Tennessee + 1 more",
      "locations": [
        {
          "city": "Rochester",
          "state": "New York"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01757288"
    },
    {
      "nct_id": "NCT03781362",
      "title": "Study of CPI-100 in Patients With Advanced Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Tumors"
      ],
      "interventions": [
        {
          "name": "CPI-100",
          "type": "DRUG"
        },
        {
          "name": "Capecitabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Coordination Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 36,
      "start_date": "2018-12-21",
      "completion_date": "2022-06-21",
      "has_results": false,
      "last_update_posted_date": "2022-07-20",
      "last_synced_at": "2026-09-26T09:13:14.343Z",
      "location_count": 3,
      "location_summary": "Grand Rapids, Michigan • Cleveland, Ohio • San Antonio, Texas",
      "locations": [
        {
          "city": "Grand Rapids",
          "state": "Michigan"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03781362"
    },
    {
      "nct_id": "NCT01454804",
      "title": "Pazopanib, Lapatinib or Trastuzumab in Subjects With Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Cancers"
      ],
      "interventions": [
        {
          "name": "Pazopanib",
          "type": "DRUG"
        },
        {
          "name": "Lapatinib",
          "type": "DRUG"
        },
        {
          "name": "Trastuzumab (Herceptin®)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 43,
      "start_date": "2011-10",
      "completion_date": "2015-03",
      "has_results": false,
      "last_update_posted_date": "2016-04-13",
      "last_synced_at": "2026-09-26T09:13:14.343Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01454804"
    },
    {
      "nct_id": "NCT07011667",
      "title": "A Research Study to Look at How Well CagriSema Helps People Living With Obesity Lose Weight and Maintain Weight Loss in the Long-term",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Obesity"
      ],
      "interventions": [
        {
          "name": "CagriSema (Cagrilintide B and Semaglutide I)",
          "type": "DRUG"
        },
        {
          "name": "Placebo matched to CagriSema (Cagrilintide B and Semaglutide I)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novo Nordisk A/S",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 609,
      "start_date": "2025-06-03",
      "completion_date": "2028-10-17",
      "has_results": false,
      "last_update_posted_date": "2026-07-24",
      "last_synced_at": "2026-09-26T09:13:14.343Z",
      "location_count": 46,
      "location_summary": "Costa Mesa, California • San Diego, California • Walnut Creek, California + 41 more",
      "locations": [
        {
          "city": "Costa Mesa",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Walnut Creek",
          "state": "California"
        },
        {
          "city": "Fleming Island",
          "state": "Florida"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07011667"
    }
  ]
}